Abstract:Background: Endocrine therapy is highly effective in blocking the estrogen receptor pathway in HR+/HER2- early breast cancer (EBC). However, up to 40% of patients experience relapse during or after adjuvant endocrine therapy. Here, we investigate molecular mechanisms associated with primary resistance to endocrine therapy and develop predictive models. Patients and Methods: In the WSG-ADAPT trial (NCT01779206), HR+/HER2- EBC patients underwent pre-operative short-term endocrine therapy (pET). Treatment response was determined by immunohistochemical in-situ labeling of cycling cells (G1 to M-phase) with Ki67 before and after pET. We performed targeted next generation sequencing and Infinium MethylationEPIC-based DNA methylation analysis post-pET in a discovery cohort (n=364, responder (R) and non-responder (NR) pairs matched for clinicopathologic features) and a validation cohort (n=270, unmatched). Predictive indices of endocrine resistance under both treatments were constructed using lasso penalized logistic regression. A subset of breast cancers from The Cancer Genome Atlas project (TCGA-BRCA) was used for external validation. Results: TP53 mutations were prominently associated with primary resistance to both tamoxifen (TAM) and aromatase inhibitors (AI), with AI non-responders exhibiting resistance in up to 32% of cases. Additionally, we identified distinct DNA methylation patterns in TAM and AI non-responders, with TAM non-responders showing global DNA methylation loss, associated with KRAS signaling, apical junctions and epithelial-mesenchymal transition (EMT). Conversely, we observed methylation gain in AI non-responders affecting developmental transcription factors, hypoxia and estrogen signaling. TAM or AI resistance was associated with increased methylation-inferred proportions of immune cells and decreased proportions of endothelial cells. Based on these findings and patient age, we developed the Predictive Endocrine ResistanCe Index (PERCI). PERCI stratified NR and R cases in both treatment groups and cohorts with high accuracy (ROC AUC TAM discovery 93.9%, validation 83%; AI discovery 98.6%, validation 76.9%). A simplified PERCI efficiently predicted progression-free survival in the TCGA-BRCA sub-cohort (Kaplan-Meier log-rank p-value = 0.03 between low and high PERCI groups). Conclusions: We identified genomic and epigenomic features associated with primary resistance to TMA and AI. By combining information on genomic alterations, patient age, differential methylation and tumor microenvironment (TME) composition, we developed PERCI TAM and PERCI AI as novel predictors of primary resistance, with potential additional prognostic value. Applying PERCI in a clinical setting may allow patient-specific drug selection to overcome resistance. WSG-ADAPT, NCT01779206, Registered 2013-01-25, retrospectively registered.

Molecular markers of therapeutic resistance in breast cancer.

Development and validation of multivariate predictors of primary endocrine resistance to tamoxifen and aromatase inhibitors in luminal breast cancer reveal drug-specific differences

Novel Prognostic Markers for Patients with Triple-Negative Breast Cancer

Association of EGFR Mutation or ALK Rearrangement with Expression of DNA Repair and Synthesis Genes in Never‐smoker Women with Pulmonary Adenocarcinoma

Markers of Tumor-Initiating Cells Predict Chemoresistance in Breast Cancer

The Expression of Aldehyde Dehydrogenase 1 in Invasive Primary Breast Tumors and Axillary Lymph Node Metastases is Associated with Poor Clinical Prognosis.

Quantitative Proteomics Analysis Integrated with Microarray Data Reveals That Extracellular Matrix Proteins, Catenins, and P53 Binding Protein 1 Are Important for Chemotherapy Response in Ovarian Cancers

ERCC1, RRM1 and BRCA1 Mrna Expression Levels and Clinical Outcome of Advanced Non-Small Cell Lung Cancer.

Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer

The Expression of Aldehyde Dehydrogenase Family in Breast Cancer.

Biomarkers and Multiple Drug Resistance in Breast Cancer

Identification of Candidate Molecular Markers Predicting Chemotherapy Resistance in Non-Small Cell Lung Cancer

ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel

Expression Of Aldh1 And Tgf Beta 2 In Benign And Malignant Breast Tumors And Their Prognostic Implications

Abstract PD07-09: Hypoxia (VEGF-S) Signature and CRYAB Predict Response to Neoadjuvant Anthracycline/Taxane Containing Chemotherapy Within Triple Negative and Unselected Breast Tumors

Predictive markers of endocrine response in breast cancer

Aldehyde Dehydrogenase 1 Expression is Correlated with Poor Prognosis in Breast Cancer

Aldehyde Dehydrogenase 1 Expression Predicts Chemoresistance and Poor Clinical Outcomes in Patients with Locally Advanced Cervical Cancer Treated with Neoadjuvant Chemotherapy Prior to Radical Hysterectomy.

Expression of Bcl-2 but not Bax or p53 correlates with in vitro resistance to a series of anticancer drugs in breast carcinoma

Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer

Estrogen receptor—positive breast cancer survival prediction and analysis of resistance–related genes introduction